A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE).

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE).

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2016

At a glance

  • Drugs Tabalumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms ILLUMINATE-2
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Oct 2016 Pooled analysis (n=1760) of gene expression and pharmacodynamic induced changes from ILLUMINATE-1 and ILLUMINATE-2 trials published in the Arthritis and Rheumatology.
    • 20 Aug 2015 Results published in the Annals of the Rheumatic Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top